Hostname: page-component-586b7cd67f-t7czq Total loading time: 0 Render date: 2024-11-29T07:31:16.174Z Has data issue: false hasContentIssue false
  • English
  • Français

The effect of antidepressant treatment on white matter integrity in Major Depression

Published online by Cambridge University Press:  01 September 2022

S. Tourjman ,
S. Potvin ,
R. Milan ,
E. Kouassi  and
D. Luck
S. Tourjman*
Affiliation:
Institut Universitaire en Santé Mentale de Montréal, Psychiatry, Montréal, Canada
S. Potvin
Affiliation:
Institut Universitaire en Santé Mentale de Montréal, Psychiatry, Montréal, Canada
R. Milan
Affiliation:
McGill University, Medicine, Montréal, Canada
E. Kouassi
Affiliation:
McGill University, Medicine, Montréal, Canada
D. Luck
Affiliation:
McGill University, Medicine, Montréal, Canada
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

White matter abnormalities have been identified in major depressive disorder (MDD). Although several diffusion tensor imaging studies found decreased fractional anisotropy (FA) in MDD, the effect of antidepressants (AD) treatment on white matter integrity has been insufficiently studied.

Objectives

We sought to examine the effect of AD treatment of MDD on white matter, using DTI, in responders compared to nonresponders.

Methods

We included 25 individuals with MDD (HAMD >/=20) without inflammatory, unstable medical/neurological conditions or prolonged duration (> 1 year),or AD or anti-inflammatory treatment >/=1 week preceding first evaluation. Evaluation before treatment and at 16 weeks included depression rating scales, a cognitive battery, inflammatory markers and MRI. Desvenlafaxine was initiated at 50mg with a possible increase to 100mg at 8 weeks.

Results

Changes included: increased volume in responders in the right Inferior Fronto-Occipital fasciculus (p=0.0315) and Superior Longitudinal Fasciculus part 3 (p=0.0050); in remitters in the right Inferior Fronto-Occipital fasciculus (p=0.0359) and Superior Longitudinal Fasciculus part 2 (p<0.05) and 3 (p=0.0481); decreased volume in responders in the left Superior Longitudinal Fasciculus part 1 (p=0.0147) and left Corona Radiata(p<0.05); and in remitters in the left Superior Longitudinal Fasciculus part 1 (p=0.0109) and the Corpus Callosum part 5 (p<0.05); decreased FA in the right Cortico Spinal Tract in remitters (p=0.0175) and responders (p=0.0272), and an increase in FA in the left Uncinate Fasciculus in nonremitters (p=0.0493). These results lose significance following Bonferroni correction.

Conclusions

Overall, AD treatment of MDD was not associated with significant changes in FA, whole brain, or specific tract volume in this study.

Disclosure

This research was funded by Pfizer Canada.

Keywords

NeuroimagingDepressionantidepressantDTI
Type
Abstract
Information
European Psychiatry , Volume 65 , Special Issue S1: Abstracts of the 30th European Congress of Psychiatry , June 2022 , pp. S213
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.